"Spinning" a Solution for Tracheal Surgery
Joyce Laird Innovative use of an old technology to solve a new challenge. Macchiarini performed the world’s first transplant of a regenerated trachea in 2008. The patient is still alive today, more than five years later. Green explained that all of the other heart and lung regeneration work at that time was being done on animals. He saw this as a very strong incentive to expand into the regeneration of all types of hollow organs using bioreactive technology. read more
AbstractPrimary graft dysfunction (PGD) remains the leading cause of early mortality post-heart transplantation. Despite improvements in mechanical circulatory support and critical care measures, the rate of PGD remains significant. A recent consensus statement by the International Society of Heart and Lung Transplantation (ISHLT) has formulated a definition for PGD. Five years on, we look at current concepts and future directions of PGD in the current era of transplantation.
Long-term survival after lung transplantation remains limited by the development of chronic lung allograft dysfunction (CLAD), which affects approximately 50% of lung recipients by 5 years post-transplant.1 Given the lack of a proven therapy once CLAD is diagnosed, risk factor mitigation is a key preventive strategy. The principal risk factor for CLAD is A-grade acute cellular rejection (ACR). A-grade ACR is diagnosed by transbronchial biopsy (TBB), exhibiting perivascular mononuclear cell infiltrates that extend into the interstitium with higher grade rejection.
CONCLUSION: These new recommendations, close to French practices, help clinicians to find the right time for referral of patients to transplantation centers. This is crucial for the prognosis of lung transplantation. PMID: 31006579 [PubMed - as supplied by publisher]
Geng-Hong Xia1†, Chao You1,2†, Xu-Xuan Gao1, Xiu-Li Zeng1, Jia-Jia Zhu1, Kai-Yu Xu3, Chu-Hong Tan1, Ruo-Ting Xu1, Qi-Heng Wu1, Hong-Wei Zhou3, Yan He4*‡ and Jia Yin1*‡ 1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China 2Department of Neurology, The First People's Hospital of Zunyi, Zunyi, China 3State Key Laboratory of Organ Failure Research, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China 4Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical Univ...
Conclusions: Our results show worldwide efficacy of BM-MSCs in improving functional outcomes in pre-clinical animal models of stroke and support testing these cells in clinical trials in various ranges of time windows using different delivery routes. The continued growing number of publications showing functional benefit of BM-MSCs are now adding limited value to an oversaturated literature spanning 18 years. Researchers should focus on identifying definitive mechanisms on how BM-MSCs lead to benefit in stroke models. Introduction Ischemic stroke is the 5th leading cause of death and the leading cause of long term di...
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic an...
Australia ’s increasing organ donor rate has translated to increased lung donor referrals and subsequent lung transplantation (LTx). The LTx sector attempts to utilise as many organs as possible—but in reality, not all are used. This analysis aims to assess the utility and efficiency of donor lung referra ls to the Alfred Hospital.